Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients | Aplastic Anemia & MDS International Foundation

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients

Journal Title: 
Leukemia
Primary Author: 
Santini, V
Author(s): 
Valeria Santini, Pierre Fenaux, Aristoteles Giagounidis, Uwe Platzbecker, Alan F List, Torsten Haferlach, Jim Zhong, Chengqing Wu, Konstantinos Mavrommatis, C L Beach, Kyle J MacBeth, Antonio Almeida
Original Publication Date: 
Monday, July 13, 2020
Bone Marrow Diseases: